Oncology Central

Shares of Advaxis fall following patient death

Shares in Advaxis have dropped more than 21% after the company announced that the FDA has placed a clinical hold on a Phase I/II study investigating axalimogene filolisbac in combination with AstraZeneca’s Imfinzi ® (durvalumab) for the treatment of patients with advanced, recurrent or refractory HPV-associated cervical cancer and HPV-associated head and neck cancer.

The FDA halted the trial after the death from respiratory failure was reported at the end of February. The patient’s death followed the sixth combination cycle in the trial, the company stated.

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.




News Headlines

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.